Barclays
PACB icon

Barclays’s Pacific Biosciences PACB Stock Holding History

Barclays’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,300
Closed -$149K – 5447
2021
Q4 		$149K Buy
+7,300
New +$176K ﹤0.01% 3640

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's PACB Position: Q2 2026 in Review

Barclays increased its Pacific Biosciences (PACB) stake by 25% in Q2 2026, buying an estimated $79.4K and bringing the position to 276,988 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Barclays first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.52M in Q4 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Barclays held 276,988 shares of Pacific Biosciences worth $465K as of Q2 2026.
  • Barclays bought 54,641 Pacific Biosciences shares in Q2 2026, an estimated $79.4K.
  • Pacific Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3271 holding.
  • Barclays first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Pacific Biosciences position peaked at $6.52M in Q4 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.